What really happened

Theranos promised to revolutionize blood testing. From a single fingerprick of blood, its proprietary “Edison” device was supposed to run more than 200 different tests — a fraction of the time and cost of conventional labs. The 19-year-old Stanford dropout Elizabeth Holmes became the face: black turtleneck à la Steve Jobs, charismatic stage presence, a vision of “democratizing diagnostics”.

The Theranos board was a who-is-who: Henry Kissinger, James Mattis (later US Secretary of Defense), the Shultz family, Larry Ellison as investor. Theranos secured partnerships with Walgreens and Safeway to roll out the blood tests in pharmacies. 2014 valuation: $9 billion. Holmes was on every business-magazine cover.

But the Edison machines did not work. They could only run roughly 12 of the 200 promised tests, and even those with inadequate accuracy. Most of the patient tests at Walgreens locations were quietly redirected to standard Siemens machines — a direct contract breach with Walgreens. WSJ reporter John Carreyrou exposed this in October 2015 after months of whistleblower interviews. CMS shut down the Theranos lab in 2016. The SEC charged Holmes with investor fraud in 2018. Theranos was liquidated in September 2018. In January 2022 Holmes was sentenced to 11 years in prison.

The warning signs everyone ignored

Multiple early warnings were ignored or suppressed. Theranos CSO Ian Gibbons warned in 2013 about the device’s non-functionality — he took his own life shortly before his scheduled testimony to SEC lawyers. Tyler Shultz, grandson of board member George Shultz, alerted as an internal whistleblower in 2014 — he was pressured by Theranos lawyers and had to spend over $400,000 on his legal defense.

Structurally, everything was opaque: Theranos published no peer-reviewed studies on the accuracy of its tests. They allowed no external audits. The 200-tests claim was never independently verified. Yet sophisticated backers invested — Rupert Murdoch lost $125M, the Walton family $150M, Mexico’s Carlos Slim $30M. The pitch was: too good to be true, but if it works it changes the world — i.e. a 1%-probability bet on a trillion-dollar industry.

What investors can learn today

First: cult-of-personality business models are high risk. When everything hinges on a single person and that person suppresses criticism, the risk cannot be measured. Second: scientific claims require scientific evidence. A tech firm selling medical devices that refuses to provide peer-reviewed proof should raise red flags. Third: boards drawn from politics and military do not substitute for domain expertise. Henry Kissinger and James Mattis had no clue about blood-test diagnostics — their presence was marketing, not oversight.